BioCentury | Mar 17, 2020
Finance

With strengthened balance sheet, Keros is latest biotech looking to test IPO market

Keros’ $56 million series C round early this month appears to be the last stepping stone towards an IPO intended to fund its ongoing clinical work. Despite the volatile public markets, the hematological and musculoskeletal...
BC Extra | Jan 29, 2020
Company News

Management tracks: Century Therapeutics, Passage, Forbion, Bavarian, Disc, Biocartis, QuantuMDx and more

Century Therapeutics LLC appointed Joseph Jimenez, former CEO of Novartis AG (NYSE:NVS; SIX:NOVN), to its board. Jimenez retired in 2018 after eight years at the pharma’s helm, leading it through multiple patent expirations, business integrations...
BC Extra | Nov 26, 2019
Company News

Nov. 25 Company Quick Takes: FDA approves GBT's sickle cell therapy; plus ChemoCentryx, Astellas, La Jolla, Sorrento, Aquestive

GBT's sickle cell therapy snags accelerated approval  FDA granted accelerated approval to Oxbryta voxelotor from Global Blood Therapeutics Inc. (NASDAQ:GBT) to treat sickle cell disease three months ahead of its Feb. 26 PDUFA date, marking...
BC Innovations | Oct 30, 2019
Emerging Company Profile

Disc Medicine: Seeking Iron Balance via Hepcidin

Disc debuted Tuesday with a $50 million series A round and a pair of hepcidin modulators aimed at carving a place in hematological disorders, alongside a host of disease-modifying therapies that are much closer to...
BC Week In Review | Mar 30, 2018
Clinical News

Protagonist discontinues Phase IIb of PTG-100 for UC

Protagonist Therapeutics Inc. (NASDAQ:PTGX) discontinued the Phase IIb PROPEL trial of once-daily PTG-100 to treat moderate to severe ulcerative colitis. Protagonist said it will decide whether to start a Phase II/III trial of the candidate...
BC Extra | Mar 26, 2018
Clinical News

Protagonist shares halved on UC failure

Protagonist Therapeutics Inc. (NASDAQ:PTGX) was down $11.68 (57%) to $8.75 on Monday after the company discontinued the Phase IIb PROPEL trial of PTG-100 to treat moderate to severe ulcerative colitis. Protagonist said it will decide...
BC Innovations | Jun 8, 2017
Targets & Mechanisms

Pumping iron

A natural compound from the Japanese Hinoki tree may hold the answer to iron transport diseases treated inadequately by phlebotomy, chelation therapy or dietary supplements. In Science last month, a University of Illinois -led group...
BC Week In Review | Mar 3, 2017
Company News

Pieris, Aska deal

Pieris granted Aska an exclusive option to develop and commercialize PRS-080 in Japan, South Korea and undisclosed other Asian markets outside of China. Pieris will receive $2.8 million up front. If the option is exercised,...
BioCentury | Nov 21, 2016
Product Development

AML Takes ASH

An analysis of the nearly 5,000 abstracts to be presented at the American Society of Hematology meeting shows research on acute myelogenous leukemia will dominate. BioCentury analyzed more than 2,200 abstracts concerning clinical research, including...
BC Innovations | Nov 17, 2016
Product R&D

Hemorrhaging targets

An analysis of the almost 5,000 abstracts set to be presented at the 2016 American Society of Hematology (ASH) meeting next month indicates this year’s hot topics in preclinical research include a spattering of new...
Items per page:
1 - 10 of 60